Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells DOI Creative Commons
Sei Morinaga,

QINGHONG HAN,

KOHEI MIZUTA

et al.

Anticancer Research, Journal Year: 2024, Volume and Issue: 45(1), P. 97 - 103

Published: Dec. 30, 2024

Background/Aim: Ivermectin was initially utilized as a veterinary medication, demonstrating efficacy against various parasites. Pancreatic cancer is currently one of the most recalcitrant diseases. The aim present study to demonstrate synergy combination recombinant methioninase (rMETase) and ivermectin eradicate human pancreatic cells in vitro. Materials Methods: MiaPaCa-2 were cultured Dulbecco's modified Eagle's medium (DMEM) with addition 10% fetal bovine serum 1 IU/ml penicillin/streptomycin. Reduction cell viability by rMETase alone their on determined WST-reagent. Four experimental groups examined vitro: control group without treatment; alone; combined rMETase. Results: IC50 for 5.9 μM. 2.93 U/ml. (5.9 μM) plus (2.93 U/ml) synergistically greatly reduced cells, compared (80% reduction vs. 45% reduction, respectively p<0.05). Conclusion: effectively eradicated cells. results indicate future clinical potential rMETase, administered orally patients dietary supplement, oral cancer.

Language: Английский

Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem DOI Creative Commons
Sei Morinaga,

QINGHONG HAN,

KOHEI MIZUTA

et al.

Anticancer Research, Journal Year: 2024, Volume and Issue: 44(9), P. 3785 - 3791

Published: Aug. 28, 2024

Drug resistance has been a recalcitrant problem for sarcoma patients many decades. Trabectedin is second-line chemotherapy soft-tissue that often leads to and death of the patients. The objective present study was address issue trabectedin-chemoresistance in HT1080 fibrosarcoma cells by combining recombinant methioninase (rMETase) with trabectedin examining their efficacy on trabectedin-resistant vitro.

Language: Английский

Citations

2
Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma DOI Creative Commons
Sei Morinaga,

QINGHONG HAN,

KOHEI MIZUTA

et al.

Anticancer Research, Journal Year: 2024, Volume and Issue: 44(9), P. 3777 - 3783

Published: Aug. 28, 2024

A major challenge in treating soft-tissue sarcoma is the development of drug resistance. Eribulin, an anti-tubulin agent, used as a second-line chemotherapy for patients with unresectable or metastatic sarcoma. However, most advanced are resistant to eribulin and do not survive. Recombinant methioninase (rMETase) targets fundamental general hallmark cancer, methionine addiction, termed Hoffman Effect. The present study aimed show how much rMETase could increase efficacy on eribulin-resistant fibrosarcoma cells vitro.

Language: Английский

Citations

2
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse Models DOI Open Access
Sei Morinaga,

QINGHONG HAN,

KOHEI MIZUTA

et al.

In Vivo, Journal Year: 2024, Volume and Issue: 39(1), P. 120 - 126

Published: Dec. 31, 2024

Ifosfamide is used clinically with doxorubicin as first-line chemotherapy for soft-tissue sarcoma. However, ifosfamide efficacy sarcoma limited due to frequent occurence of resistance and thus more effective therapy needed. The present study aimed determine the synergy recombinant methioninase (rMETase) plus against HT1080 human fibrosarcoma cells in vitro. Additionally, also investigated a methionine-restricted diet combined nude-mouse models ifosfamide-resistant (IR-HT1080).

Language: Английский

Citations

0
Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells DOI Creative Commons
Sei Morinaga,

QINGHONG HAN,

KOHEI MIZUTA

et al.

Anticancer Research, Journal Year: 2024, Volume and Issue: 45(1), P. 97 - 103

Published: Dec. 30, 2024

Background/Aim: Ivermectin was initially utilized as a veterinary medication, demonstrating efficacy against various parasites. Pancreatic cancer is currently one of the most recalcitrant diseases. The aim present study to demonstrate synergy combination recombinant methioninase (rMETase) and ivermectin eradicate human pancreatic cells in vitro. Materials Methods: MiaPaCa-2 were cultured Dulbecco's modified Eagle's medium (DMEM) with addition 10% fetal bovine serum 1 IU/ml penicillin/streptomycin. Reduction cell viability by rMETase alone their on determined WST-reagent. Four experimental groups examined vitro: control group without treatment; alone; combined rMETase. Results: IC50 for 5.9 μM. 2.93 U/ml. (5.9 μM) plus (2.93 U/ml) synergistically greatly reduced cells, compared (80% reduction vs. 45% reduction, respectively p<0.05). Conclusion: effectively eradicated cells. results indicate future clinical potential rMETase, administered orally patients dietary supplement, oral cancer.

Language: Английский

Citations

0